The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.

ABSTRACT:

Unlabelled

The transcription factor ZNF217 is a candidate oncogene in the amplicon on chromosome 20q13 that occurs in 20% to 30% of primary human breast cancers and that correlates with poor prognosis. We show that Znf217 overexpression drives aberrant differentiation and signaling events, promotes increased self-renewal capacity, mesenchymal marker expression, motility, and metastasis, and represses an adult tissue stem cell gene signature downregulated in cancers. By in silico screening, we identified candidate therapeutics that at low concentrations inhibit growth of cancer cells expressing high ZNF217. We show that the nucleoside analogue triciribine inhibits ZNF217-induced tumor growth and chemotherapy resistance and inhibits signaling events [e.g., phospho-AKT, phospho-mitoge

SUBMITTER: Littlepage LE 

PROVIDER: S-EPMC3546490 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature